Corient Private Wealth LP Makes New Investment in Baxter International Inc. $BAX

Key Points

• Corient Private Wealth purchased 39,784 shares of Baxter International in the second quarter, valued at approximately $848,000. Institutional investors collectively own 90.19% of the company.
• Baxter reported quarterly adjusted earnings of $0.56 per share and revenue of $2.96 billion, exceeding analyst expectations, while revenue increased 5.3% year over year.
• Analysts maintain a predominantly cautious outlook, with an overall “Hold” rating and an average price target of $22.45, below the reported share price of $25.81.

Corient Private Wealth LP bought a new stake in shares of Baxter International Inc. (NYSE:BAX - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 39,784 shares of the medical instruments supplier's stock, valued at approximately $848,000.

A number of other hedge funds also recently made changes to their positions in BAX. Basepoint Wealth LLC bought a new position in Baxter International during the fourth quarter valued at about $26,000. Jones Financial Companies Lllp purchased a new stake in Baxter International during the second quarter worth about $26,000. Imprint Wealth LLC bought a new stake in Baxter International in the third quarter worth about $27,000. MUFG Securities EMEA plc bought a new stake in Baxter International in the second quarter worth about $46,000. Finally, Los Angeles Capital Management LLC bought a new stake in Baxter International in the fourth quarter worth about $46,000. 90.19% of the stock is currently owned by institutional investors.

Baxter International Stock Performance

NYSE:BAX opened at $25.81 on Friday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.32 and a current ratio of 1.95. Baxter International Inc. has a 52-week low of $15.73 and a 52-week high of $30.00. The firm has a market cap of $13.34 billion, a price-to-earnings ratio of -12.47, a PEG ratio of 3.91 and a beta of 0.60. The business's fifty day moving average is $24.73 and its 200 day moving average is $20.72.

Baxter International (NYSE:BAX - Get Free Report) last issued its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 EPS for the quarter, topping the consensus estimate of $0.37 by $0.19. The business had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $2.80 billion. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%.The firm's revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.59 EPS. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. Research analysts predict that Baxter International Inc. will post 2.04 EPS for the current year.

Baxter International Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Friday, August 28th will be given a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, August 28th. Baxter International's dividend payout ratio (DPR) is -1.93%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on BAX shares. TD Cowen increased their target price on shares of Baxter International from $20.00 to $24.00 and gave the company a "hold" rating in a research report on Monday, July 27th. Zacks Research raised shares of Baxter International from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 11th. Weiss Ratings upgraded Baxter International from a "sell (d-)" rating to a "sell (d)" rating in a research note on Friday, July 31st. Wall Street Zen raised Baxter International from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Finally, Wells Fargo & Company raised their target price on Baxter International from $19.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Friday, July 31st. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $22.45.

Baxter International Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company's primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter's offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source